Asthenozoospermia

From WikiMD's WELLNESSPEDIA

Asthenozoospermia is a medical condition characterized by decreased motility of sperm in a semen analysis. It is one of the primary causes of infertility in males.

Definition[edit]

Asthenozoospermia is defined by the World Health Organization (WHO) as a condition where the percentage of progressively motile sperm is less than 32%. It is a common finding in male infertility.

Causes[edit]

The causes of asthenozoospermia are multifactorial and can be divided into congenital and acquired causes. Congenital causes include genetic disorders such as cystic fibrosis, Kartagener syndrome, and Young syndrome. Acquired causes can be due to infections, varicocele, smoking, alcohol, drugs, environmental toxins, and aging.

Diagnosis[edit]

The diagnosis of asthenozoospermia is made by a semen analysis. The semen sample is obtained by masturbation after a period of 2-7 days of sexual abstinence. The sample is then analyzed under a microscope to assess the number, shape, and movement of the sperm.

Treatment[edit]

The treatment of asthenozoospermia depends on the underlying cause. If the cause is due to a varicocele, a varicocelectomy may be performed. If the cause is due to a hormonal imbalance, hormone therapy may be initiated. In cases where the cause is unknown, assisted reproductive technology such as intrauterine insemination (IUI), in vitro fertilization (IVF), or intracytoplasmic sperm injection (ICSI) may be considered.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.